Friday, April 24, 2015

04/24/2015 ~ Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Development Efforts Pediatric Trial

Genzyme logo

Dear NNPDF Families and Friends,

The NNPDF Central Offices have been notified that Genzyme, a Sanofi Company, has released a statement with additional details about the pediatric Phase 1 / 2 clinical trial of recombinant human acid sphingomyelinase (rhASM).

Visit the NNPDF Enzyme Replacement Therapy web page to view the the statement:

No comments:

Post a Comment